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Currently, there is no evidence of a system that ensures conti-
nuity of care and assesses treatment outcomes for these children.
http://dx.doi.org/10.1016/j.ijid.2014.03.1219
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Background: Yaws is a disﬁguring non-venereal treponemal
disease, one of the neglected tropical diseases continued to be
prevalent in isolated pockets in some of the tropical countries in
African, Asia andWestern Paciﬁc Regions of theWorldHealthOrga-
nization (WHO). It is a disease commonly seen amongmarginalized
poor section of the most neglected population. More than 50% of
the cases occur in children. Generally, it is said “yaws begins where
the road ends”.
Between 1952 and 1964, the WHO and the UNICEF embarked
on global treponema control campaigns to administer a single dose
long-acting benzathine penicillin to all yaws cases and their con-
tacts. About 50millionpeoplewere treated in46endemic countries
during the campaign. As a result, the burden the disease reduced by
more than 95 percent from 50 million to 2.5 million. Subsequently,
yaws lost its priority in the light of emerging other priority disease
control programmers and the goal of eradication was not reached.
Methods&Materials: The authors reviewed available informa-
tion on progress on yaws eradication and efﬁcacy of azithromycin
drug intervention to cure the disease.
One of the main objectives of the presentation is to advocate
global participants towards yaws disease to gain support to set a
momentum to achieve eradication by 2020.
Results: Though the extent of the endemicity is fully not known,
about 90 countries were believed to be endemic in the 1950s; 12
countries of them reported new yaws cases - 56 223 (2008) and 47
800 (2012) (WHO 2012).
Encouraged by the recent evidence of efﬁcacy of a single oral
dose of azithromycin in curing yaws disease in Papua New Guinea
and Ghana, WHO recommended single dose azithromycin-based
treatment strategy (Morges strategy 2012). Initially, a single dose
of azithromycin to entire yaws endemic community followed by
targeted treatment of cases and contacts.
Conclusion: Yaws endemic countries met in Geneva,
Switzerland in 2012 and 2013 and drafted operational guide-
lines to implement the new treatment strategy. Ghana, Papua New
Guinea, Solomon Islands and Vanuatu implemented pilot projects
to gain more experience in 2013.
World Health Assembly resolution in 2013 included yaws for
eradication by 2020.
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Prevalence of malaria and predisposing factors
to antimalarial drug resistance in Ota
G.I. Olasehinde ∗
Covenant University, Ota, Nigeria
Background: Antimalarial drug resistance has emerged as one
of the greatest challenges facing malaria control today. It has
also been implicated in the spread of malaria to new areas and
re-emergence of malaria in areas where the disease had been erad-
icated. In this study, Prevalence andpreddiposing factors tomalaria
were determined.
Methods & Materials: Prevalence of falciparum malaria was
determined by microscopic examination of Giemsa-stained blood
samples of patients who presented with fever in selected State
Hospitals in Ogun State between 2008 and 2011.Structured Ques-
tionnaires were administered to patients or/and parents of infants
to determine the factors that could lead to the development of drug
resistance by the parasite in the study population.
Results: Out of 4066 subjects screened during the period of
study, 2550 (61.1%) were positive.Highest prevalence (72%) was
recorded in children 1-5 years while the same group also had
the highest parasitaemia of 1080. The study showed that 24.6%
of the patient visit hospitals for treatment, 12.0% use local heal-
ers while 25.0% buy antimalarial drugs without prescription. It
was also observed that some use more than one method in their
management of malaria. Those who combined antimalarial drugs
with traditional medicine from local healers were found to be
17.4%. Only 18% of the sample population used Insecticide treated
mosquito nets, 42.3% use window and door nets while 13% did not
employ any mosquito preventive method.
Conclusion: Continuous use of the current antimalarial drugs
increases the chance of resistance developing to those drugs. Con-
trol of drug use and reducing exposure of parasites to the drugs are
most effective where the parasite is still sensitive to the drug.
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